Citizens reiterates Taysha Gene Therapies stock rating on therapy progress
Citizens reiterated a Market Outperform rating and an $11.00 price target for Taysha Gene Therapies (NASDAQ:TSHA) based on progress in its TSHA-102 program for Rett Syndrome. The firm remains optimistic ahead of pivotal data and regulatory feedback expected in early 2027, noting early results show improved communication and grasping abilities in patients. The article also touches on competitor Neurogene, which recently reported positive Phase 1/2 study results for NGN-401 and announced a public offering, leading to increased price targets from analysts.
Taysha’s TSHA-102 Rett Data Links Clinical Promise To Future Revenue
Taysha Gene Therapies (TSHA) reported positive early results from its REVEAL Phase 1/2 trial for TSHA-102 in Rett syndrome, showing a 100% responder rate and durable functional improvements with a favorable safety profile. The company is accelerating commercial manufacturing preparations and plans for a biologics license application in late 2026, linking current clinical success to potential future revenue streams. Investors are closely monitoring upcoming data readouts and regulatory milestones, while also considering the risks associated with Taysha remaining a loss-making company with a concentrated lead program.
Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA
This page from TradingView provides financial information for Taysha Gene Therapies, Inc. (NASDAQ: TSHA), specifically focusing on its enterprise value to EBITDA forward metric. The content indicates market data and various navigational links related to financial tools and community features on the TradingView platform.
Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. – BOATS:TSHA
This page provides financial data, specifically the Enterprise Value to EBITDA forward, for Taysha Gene Therapies, Inc. (TSHA). It highlights that the information is presented without active trading data, indicating a market closed or no-trade status at the time of viewing. The content also specifies where market and reference data are sourced from, and outlines various products and community features offered by the platform.
Price to sales forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA
This article provides a brief mention of the "Price to sales forward" metric for Taysha Gene Therapies, Inc. (NASDAQ: TSHA). It appears to be a financial data point from TradingView, indicating a period value and changes but without specific numerical details in the snippet provided. The content is primarily navigational and informational regarding the source rather than an analytical piece.
Price to sales forward of Taysha Gene Therapies, Inc. – BOATS:TSHA
The article focuses on the "Price to sales forward" metric for Taysha Gene Therapies, Inc. (TSHA), which is listed on the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data point from TradingView, indicating a specific valuation ratio for the company.
Price to book forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA
This article provides access to the "Price to book forward" financial metric for Taysha Gene Therapies, Inc. (NASDAQ: TSHA) on the TradingView platform. It details how users can find this information within the financial section of TSHA's profile, emphasizing data provided by ICE Data Services and FactSet Research Systems Inc. The content is primarily a gateway to financial data rather than a detailed analysis.
Price to earnings forward of Taysha Gene Therapies, Inc. – BOATS:TSHA
This article provides financial information for Taysha Gene Therapies, Inc. (TSHA) on the TradingView platform. It specifically looks at the company's forward price-to-earnings ratio. The content also lists various features and resources available on TradingView for financial analysis and community engagement.
Rett Data and $200 Million Raise Might Change The Case For Investing In Taysha (TSHA)
Taysha Gene Therapies recently completed a $200 million equity raise and released encouraging longer-term data from its REVEAL trial for TSHA-102 in Rett syndrome patients, showing durable functional gains and a good safety profile. Despite being delisted from some Russell indices, this data is critical for the company's future, reinforcing the importance of the ongoing pivotal REVEAL trial results due in 2027. Investors are now focused on whether a single-arm study can effectively support regulatory approval and the potential commercial success of TSHA-102.
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell 3000E Growth Benchmark
Taysha Gene Therapies, Inc. (NasdaqGS:TSHA) has been removed from the Russell 3000E Growth Benchmark. The company is a clinical-stage biotechnology firm focusing on AAV-based gene therapies for severe central nervous system monogenic diseases, with its lead program TSHA-102 targeting Rett syndrome. This news coincides with recent clinical program updates and a $200 million public offering.
Taysha Gene Therapies launches $200 million stock offering
Taysha Gene Therapies, a clinical-stage biotechnology company, has initiated an underwritten public offering of common stock and pre-funded warrants valued at $200 million. This move follows a significant 189% gain in its shares over the past year, although the stock appears overvalued by InvestingPro analysis. The company is actively developing TSHA-102 for Rett syndrome, with positive clinical trial developments and raised price targets from analysts.
Taysha Gene Therapies (NASDAQ: TSHA) prices $200M equity raise with warrants
Taysha Gene Therapies (NASDAQ: TSHA) has priced an underwritten public offering to raise approximately $200 million in gross proceeds through the sale of common stock and pre-funded warrants. The company will sell 32,500,001 common shares at $6.00 each and pre-funded warrants for 833,333 shares at $5.999 per warrant. Taysha anticipates net proceeds of $187.4 million, or $215.6 million if underwriters fully exercise their option, which is expected to fund operations and capital needs into the second half of 2028.
Taysha Gene Therapies Prices Equity Offering for ~$187.4 Million Net, Grants 5 Million Share Option
Taysha Gene Therapies announced an equity offering to sell over 33 million shares and pre-funded warrants at $6.00 per share, expecting to net approximately $187.4 million. The company has also granted underwriters an option to purchase up to 5 million additional shares, which could increase net proceeds to about $215.6 million. The offering, led by Jefferies and Goldman Sachs, is anticipated to close on June 26, 2026, to fund operations and extend its cash runway.
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
Taysha Gene Therapies announced multiple presentations at the 2026 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting, showcasing its TSHA-102 gene therapy program. The presentations will cover safety and efficacy data from the REVEAL Part A Phase 1/2 trial, insights from natural history studies supporting novel interventional study designs, and the validation of the Rett Syndrome Developmental Milestone Assessment as a primary endpoint. Additionally, preclinical data on TSHA-102's superior MeCP2 expression and design will be featured.
Taysha lines up TSHA-102 data on Rett syndrome at June 29 meeting
Taysha Gene Therapies (Nasdaq: TSHA) will present multiple updates on its TSHA-102 program for Rett syndrome at the 2026 IRSF Rett Syndrome Scientific Meeting from June 29 to July 1, 2026. The presentations will include longer-term REVEAL Part A clinical data, natural history insights, validation of the Rett Syndrome Developmental Milestone Assessment as a primary endpoint, and preclinical MeCP2 expression data. This announcement highlights positive progress and FDA-supported endpoint work, although elevated short interest remains a risk.
Taysha Gene Therapies Down Over 11%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk
Taysha Gene Therapies (TSHA) stock is down over 11% today, experiencing its largest percentage decrease since May 2025. This downturn follows five consecutive days of gains, during which the stock rose by 4.2%. The current trading volume is significantly lower than its 65-day average.
Taysha Gene Therapies Inc Files For Mixed Shelf Offering Of Up To $200 Million - SEC Filing
Taysha Gene Therapies Inc has filed for a mixed shelf offering of up to $200 million, as disclosed in an SEC filing. This information was reported as part of standard financial news.
Taysha Gene Therapies prices $200M stock offering at $6 per share
Taysha Gene Therapies has priced an underwritten public offering of 32,500,001 shares of common stock at $6.00 per share, aiming to raise approximately $200 million. The company also offered pre-funded warrants and granted underwriters a 30-day option for additional shares. This offering occurs while TSHA shares are trading above the offering price, having seen a 184% return over the past year.
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies announced the pricing of a public offering of 32,500,001 shares of common stock at $6.00 per share and pre-funded warrants for 833,333 shares at $5.999 per warrant. The company expects to raise approximately $200.0 million from this offering, which is anticipated to close around June 26, 2026. This capital raise will support the clinical-stage biotechnology company's work on AAV-based gene therapies for severe monogenic diseases of the central nervous system.
Taysha prices $200M offering as closing nears June 26
Taysha Gene Therapies (Nasdaq: TSHA) announced the pricing of an underwritten public offering totaling approximately $200 million. The offering includes 32,500,001 common shares at $6.00 each and pre-funded warrants for 833,333 shares at $5.999 each, with an option for underwriters to purchase an additional 5,000,000 shares. The closing is expected around June 26, 2026, subject to customary conditions, with proceeds intended to support the company's gene therapy programs.
Taysha Gene Therapies begins $200M offering with pre-funded warrants
Taysha Gene Therapies (TSHA) has commenced an underwritten public offering of common stock and pre-funded warrants aiming to raise approximately $200 million. The company will offer all securities, with underwriters having a 30-day option to purchase an additional 15%. This announcement led to a 7.35% decline in TSHA's stock price, indicating a negative market reaction due to potential dilution for existing shareholders.
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies, Inc. announced the commencement of an underwritten public offering of $200.0 million shares of its common stock and pre-funded warrants. The offering is subject to market conditions, and the company also intends to grant the underwriters a 30-day option to purchase an additional 15% of the shares. Jefferies, Goldman Sachs & Co. LLC, Piper Sandler, and Cantor are acting as joint book-running managers.
Jefferies Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)
Jefferies has reiterated its Buy rating for Taysha Gene Therapies (TSHA), setting a price target of $13.00. This follows BMO Capital's similar Buy rating and $14.00 price target. The company reported a GAAP net loss of $42.41 million for the quarter ending March 31, compared to a $21.53 million loss and $2.3 million revenue in the prior year.
Taysha Gene Therapies stock tumbles on $200M stock offering
Taysha Gene Therapies Inc. (NASDAQ: TSHA) shares fell 8.5% in after-hours trading following the announcement of a $200 million stock and warrant offering. The clinical-stage biotechnology company will offer common stock and pre-funded warrants, with underwriters having an option to purchase an additional 15%. This offering, subject to market conditions, is being managed by several financial firms.
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $14
BMO Capital has reiterated its Buy rating on Taysha Gene Therapies (TSHA.US) and increased its price target to $14. This indicates continued confidence from the firm in the company's prospects.
TSHA Maintained by B of A Securities -- Price Target Raised to $10.00
B of A Securities analyst Tazeen Ahmad maintained a 'Buy' rating on Taysha Gene Therapies (TSHA), increasing the price target from $9.00 to $10.00, suggesting an 11.11% potential upside. Despite this optimistic outlook, GuruFocus indicates that TSHA is significantly overvalued by 832.9% with a low GF Score™ of 27, and recent insider activity shows $0.9 million in stock divestments. This creates a mixed picture for investors, highlighting analyst confidence alongside concerns about valuation and underlying financial weaknesses.
Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome - Slideshow (NASDAQ:TSHA)
Taysha Gene Therapies, Inc. (TSHA) has published a slide deck updating on longer-term clinical data and program progress for TSHA-102, their gene therapy candidate for Rett Syndrome. This information was shared in conjunction with an event. The article highlights the company's continuous efforts in developing treatments for this neurological disorder.
Citizens raises Taysha Gene Therapies price target on trial data By Investing.com
Citizens has increased its price target for Taysha Gene Therapies (NASDAQ: TSHA) to $11.00 from $8.00, maintaining a Market Outperform rating. This adjustment follows updated REVEAL Part A trial data, which showed an 83% response rate at six months, increasing to 100% at 12 months, significantly exceeding the FDA's 33% threshold. The company also reported a net loss of $0.12 per share for Q1 2026 and completed dosing in its pivotal REVEAL trial for Rett syndrome.
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
Taysha Gene Therapies has completed dosing in its REVEAL pivotal trial for TSHA-102, an investigational gene therapy for Rett syndrome. The company reported positive longer-term clinical data from Part A of its Phase 1/2 trials, showing durable and deepening treatment effects, with patients gaining multiple functional milestones. Taysha plans to engage with the FDA in early 2027 to discuss potential Biologics License Application (BLA) submission based on the six-month interim analysis of the pivotal trial.
TSHA Maintained by Needham -- Price Target Held at $12.00
Needham analyst Gil Blum has maintained a "Buy" rating for Taysha Gene Therapies (TSHA) and kept its price target at $12.00, reflecting confidence in the company's future growth despite current market conditions. However, GuruFocus identifies TSHA as significantly overvalued with a GF Value™ of $0.70 versus a current price of $6.53, alongside a low GF Score™ of 31/100 primarily due to weak profitability. Insider activity also shows more selling than buying, suggesting caution for potential investors.
Taysha Gene Therapies (TSHA) Stock Could Be 47.5% Undervalued After Rett Trial Progress
Taysha Gene Therapies' (TSHA) stock is considered 47.5% undervalued following positive progress in its REVEAL trial for TSHA-102 in Rett syndrome, including completion of patient dosing and promising safety and efficacy data. The company's valuation of $1.84 billion and current trading price of $6.42 are well below analyst targets and intrinsic estimates, suggesting potential for significant future growth if regulatory approvals are achieved. Investors are now evaluating whether the market adequately accounts for these developments, especially given the ongoing market optimism surrounding the company.
TSHA Gene Therapies (Nasdaq: TSHA) shows 100% Rett response, eyes TSHA-102 BLA
Taysha Gene Therapies (Nasdaq: TSHA) has reported significant progress for its TSHA-102 gene therapy for Rett syndrome, including the completion of dosing in its REVEAL pivotal trial and positive longer-term data from its Phase 1/2 Part A study. The data shows a 100% developmental milestone response rate in Part A patients and robust functional gains, with TSHA-102 being generally well-tolerated. The company anticipates a biologics license application (BLA) submission based on a 6-month interim analysis from the pivotal trial, with FDA feedback expected in the first half of 2027.
TSHA: TSHA-102 showed durable, accumulating functional gains and strong safety in Rett syndrome trials
TSHA-102 has completed dosing in the pivotal REVEAL trial for Rett syndrome, demonstrating durable, accumulating functional gains and a strong safety profile in all Part A patients over 12 months. Interim data and FDA feedback for an upcoming BLA submission are anticipated in the first half of 2027. This signifies a positive advancement for Taysha Gene Therapies in its Rett syndrome treatment development.
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
Taysha Gene Therapies has completed dosing in its REVEAL pivotal trial for TSHA-102, a gene therapy for Rett syndrome, and reported positive longer-term data from its Phase 1/2 trials. The data indicates that TSHA-102 is generally well-tolerated and shows durable, deepening functional gains in patients, supporting a potential Biologics License Application (BLA) submission based on the 6-month interim analysis. The company anticipates engaging with the FDA in early 2027 to discuss next steps for BLA submission.
Taysha Gene Therapies stock rises on Rett syndrome trial data By Investing.com
Taysha Gene Therapies Inc. (NASDAQ: TSHA) shares rose in premarket trading after the company completed dosing in its pivotal trial for Rett syndrome and reported positive longer-term clinical data. The company's TSHA-102 treatment for Rett syndrome was generally well-tolerated, with patients showing significant developmental milestone gains and functional improvements. Topline data and FDA feedback on the BLA submission are anticipated in the first half of 2027.
Why Taysha Gene Therapies (TSHA) Is Up 12.4% After Institutions Tighten Their Grip On Shares
Taysha Gene Therapies (TSHA) saw a 12.4% stock increase after institutional investors, including Morgan Stanley and BlackRock, significantly raised their holdings to over 100% of available shares, coinciding with positive technical trading signals. Despite this institutional interest and bullish indicators, the company's financial health shows a Q1 2026 net loss of US$42.41 million, with high hopes resting on the success of its TSHA-102 drug and the pivotal REVEAL program. The article emphasizes that while institutional accumulation offers near-term focus, the core investment risks related to TSHA-102 data, ongoing losses, and regulatory dependency remain significant.
Taysha Gene Therapies Inc (TSHA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Taysha Gene Therapies Inc (TSHA), listing its major individual shareholders and institutional holdings. It provides data on the proportion of shares held by various investor types and historical institutional shareholding trends, along with recent shareholder activity. The information is current as of May 10th for major shareholders and April 1st for institutional holdings report.
Taysha Gene Therapies Inc (TSHA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Taysha Gene Therapies Inc (TSHA) stock, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split events. The article also includes current stock performance data and market capitalization.
Earnings call transcript: Taysha Gene Therapies Q1 2026 misses EPS and revenue targets
Taysha Gene Therapies reported a Q1 2026 net loss of $0.12 per share, missing the analyst consensus of a $0.10 loss, and recorded no revenue against an $850,000 forecast. Despite the financial misses, the stock saw a slight pre-market increase, driven by promising clinical trial results for its lead gene therapy TSHA-102 for Rett syndrome and a strong cash position extending into 2028. The company is confident in its regulatory pathway, with ongoing clinical trials and positive FDA alignment.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies has announced an inducement grant to four new employees under Nasdaq Listing Rule 5635(c)(4). This grant, made on June 1, 2026, includes restricted stock units representing 714,700 shares and options to purchase 468,600 shares of the company's common stock. The inducement is designed to attract and retain key talent, with vesting spread over a four-year period.
Four new Taysha hires get 714,700 RSUs and 468,600 options
Taysha Gene Therapies granted equity awards to four new employees on June 1, 2026, including 714,700 Restricted Stock Units (RSUs) and options for 468,600 shares, with an exercise price of $5.97. These awards, issued under the 2023 Inducement Plan according to Nasdaq Listing Rule 5635(c)(4), vest over four years, contingent on continued service. This action aligns with Taysha's ongoing strategy of using equity compensation to attract and retain talent as it advances its clinical programs.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies, Inc. announced an inducement grant to four new employees, totaling 714,700 restricted stock units and options to purchase 468,600 shares of common stock. These grants were made under the company's 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), designed to incentivize new hires. The stock options have an exercise price of $5.97, aligning with the closing price on the grant date.
Taysha Gene Therapies (NASDAQ: TSHA) holders approve board, auditor and annual say-on-pay
Taysha Gene Therapies (NASDAQ: TSHA) shareholders approved key proposals at their 2026 annual meeting, including the election of Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. as directors, and the ratification of Deloitte & Touche LLP as the independent auditor. Shareholders also gave non-binding advisory approval for executive officer compensation and expressed a preference for annual say-on-pay votes. The high shareholder turnout, with 84.86% of shares represented, indicates strong engagement in the company's governance.
Taysha (TSHA) director receives RSU and stock option awards, lifts holdings
Taysha Gene Therapies director John A. Stalfort III received 21,335 restricted stock units (RSUs) and 42,671 stock options. These awards are part of his compensation and vest on the earlier of June 1, 2027, or the next annual stockholders meeting, contingent on his continued service. Following these grants, his direct and indirect holdings in Taysha common stock remain substantial, indicating these are routine compensation awards rather than a significant change in his strategic position.
Taysha Gene Therapies (TSHA) director gets RSU and stock option grants
Taysha Gene Therapies director Phillip B. Donenberg received equity compensation, including 21,335 restricted stock units (RSUs) and an option to purchase 42,671 shares of common stock. The RSUs vest on the earlier of June 1, 2027, or the next annual stockholders' meeting, subject to continued service. Following these grants, Donenberg directly holds 241,289 shares of Common Stock.
Equity awards for Taysha (TSHA) director Alison S. Long detailed
Taysha Gene Therapies' director Alison S. Long has been granted equity compensation awards, including 21,335 restricted stock units (RSUs) and stock options for 42,671 shares. These awards are contingent on her continued service on the board and are not open-market transactions. Following these grants, Long directly holds 127,178 shares of common stock and 42,671 stock options.
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $10
BMO Capital has reiterated its Buy rating for Taysha Gene Therapies (TSHA.US) and maintained its target price at $10. This indicates ongoing confidence from the analyst firm in the company's prospects.
Taysha Gene Therapies: Shortened Timeline Increases The Potential (NASDAQ:TSHA)
Taysha Gene Therapies (TSHA) is now solely focused on its TSHA-102 drug for Rett syndrome, having discontinued its previous pipeline. The company is considered a "Buy" due to strong cash reserves, promising early data for TSHA-102, and an accelerated FDA pathway that bypasses Phase 3. TSHA-102's miRARE technology offers a safety advantage over a competitor, with pivotal data expected in late 2026 and potential commercialization by 2027/2028.
Taysha Gene Therapies stock hits all-time high at 5.49 USD
Taysha Gene Therapies Inc. (TSHA) stock recently reached an all-time high of $5.49, reflecting strong investor confidence despite a recent pullback from its 52-week high of $7.30. The company's innovative gene therapy solutions have driven an impressive nearly 100% rise in stock value over the past year. However, recent financial results for Q1 2026 showed a net loss of $0.12 per share and no revenue, falling short of analyst expectations and indicating a need for strategic adjustments.
Taysha Gene Therapies stock hits all-time high at 5.49 USD
Taysha Gene Therapies (TSHA) stock recently hit an all-time high of $5.49 and has seen an impressive 100% rise over the past year, reflecting growing investor confidence despite trading above its Fair Value. However, the company reported a net loss of $0.12 per share and no revenue for Q1 2026, missing analyst expectations. Investors are monitoring the company's next strategic moves closely.
